Related Experiment Video
Updated: Aug 1, 2026
Photodynamic Therapy with Blended Conducting Polymer/Fullerene Nanoparticle Photosensitizers
Published on: October 28, 2015
Exploring Si-phthalocyanines with different valency for PSMA-targeted photodynamic therapy: Synthesis and preclinical
Valentina Dinatale1, Martina Capozza2, Rachele Stefania3
1Department of Molecular Biotechnology and Health Sciences, University of Turin, Piazza Nizza 44bis, Turin, Italy; Department of Radiology and Nuclear Medicine, Erasmus MC Cancer Institute, Erasmus University Medical Center, 's-Gravendijkwal 230, Rotterdam, the Netherlands.
Abstract:
Prostate cancer remains a significant health concern, with existing treatments often proving invasive or inadequate in preventing recurrence. This study explores the development and preclinical validation of silicon-phthalocyanine (SiPc)-based photosensitizers (PSs) targeted at prostate-specific membrane antigen (PSMA) for photodynamic therapy (PDT). Two PSMA-targeted SiPcs, monovalent and bivalent, were synthesized with axial conjugation through Si-O-C linkages to evaluate their efficacy and specificity. The bivalent SiPc-PQ-(PSMAi)2 demonstrated superior optical properties, reduced aggregation, and enhanced target specificity compared to the monovalent SiPc-PQ-PSMAi. Cellular and in vivo assays confirmed its high PSMA-specific uptake, potent photoinduced cytotoxicity mediated by reactive oxygen species, and significant tumor growth inhibition post-PDT. These findings underscore the potential of bivalent SiPc-PQ-(PSMAi)2 as an effective agent for targeted PDT, combining imaging and therapeutic capabilities for improved prostate cancer management. Further optimization and clinical evaluation could establish its role in theranostic strategies to enhance surgical outcomes and reduce recurrence.
Insights
Researchers developed a new bivalent silicon-phthalocyanine (SiPc) for targeted photodynamic therapy (PDT) in prostate cancer. This PSMA-targeted agent shows enhanced specificity and potent tumor inhibition, offering a promising theranostic approach.
Area of Science:
- Biomedical Engineering
- Oncology
- Photochemistry
Background:
- Prostate cancer treatment faces challenges with recurrence and invasiveness of current therapies.
- Photodynamic therapy (PDT) offers a less invasive treatment modality.
- Targeting prostate-specific membrane antigen (PSMA) enhances treatment specificity.
Purpose of the Study:
- To develop and preclinically validate novel silicon-phthalocyanine (SiPc)-based photosensitizers (PSs) targeted to PSMA for prostate cancer PDT.
- To compare the efficacy and specificity of monovalent versus bivalent PSMA-targeted SiPcs.
- To evaluate the theranostic potential of these agents.
Main Methods:
- Synthesis of monovalent (SiPc-PQ-PSMAi) and bivalent (SiPc-PQ-(PSMAi)2) PSMA-targeted SiPcs.
- Evaluation of optical properties, aggregation, and target specificity.
- In vitro cellular assays for uptake and phototoxicity (reactive oxygen species generation).
- In vivo studies assessing tumor uptake and therapeutic efficacy in a preclinical model.
Main Results:
- The bivalent SiPc-PQ-(PSMAi)2 exhibited superior optical properties and reduced aggregation compared to the monovalent form.
- Enhanced PSMA-specific uptake and potent photoinduced cytotoxicity were observed for the bivalent agent.
- Significant inhibition of tumor growth was achieved post-PDT with the bivalent SiPc-PQ-(PSMAi)2.
- The bivalent agent demonstrated high specificity for PSMA-expressing cells and tumors.
Conclusions:
- Bivalent SiPc-PQ-(PSMAi)2 is a highly effective agent for PSMA-targeted photodynamic therapy in prostate cancer.
- This agent shows potential as a theranostic tool, combining imaging and therapeutic capabilities.
- Further clinical evaluation is warranted to establish its role in improving prostate cancer management and reducing recurrence.
